The UK medicines regulator has announced significant new restrictions on the use of the Chikungunya vaccine, IXCHIQ, in a move that will directly affect many diaspora travellers planning trips to Africa, the Caribbean, Asia and other tropical regions.
On 11 February 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that the vaccine should now only be used in adults aged 18 to 59 years. It should not be given to people aged 60 and over, or to individuals of any age who have high blood pressure, heart disease, diabetes, or chronic kidney disease.
For many in the UK’s African and Caribbean diaspora who travel frequently to visit family, attend events, or invest back home, this update is not just a technical regulatory adjustment. It is personal.
Why the UK Has Restricted the IXCHIQ Vaccine
The decision follows advice from the Commission on Human Medicines, the government’s independent expert advisory body. The restriction comes after a review of global safety data showing 28 cases of serious adverse reactions linked to the vaccine, including three fatalities.
While the overall number is small relative to global vaccination figures, UK regulators concluded that tighter eligibility criteria were necessary to protect those at higher risk of complications.
The vaccine must also not be used in individuals who are immunodeficient or immunosuppressed, including people with IgA deficiency or a history of thymus disorder or thymectomy.
For healthy adults aged 18 to 59 without the listed medical conditions, the benefits of vaccination are still considered favourable if they are at risk of exposure to chikungunya virus.
What Is Chikungunya and Why It Matters to Diaspora Travellers
Chikungunya virus is spread by infected mosquitoes and is present in parts of Africa, Southeast Asia, India, the Americas and the Pacific region. It is not spread through casual contact such as coughing or touching.
Most people who contract chikungunya experience sudden high fever and severe joint pain. Other symptoms can include headache, muscle pain, swelling and rash. While most patients recover fully within seven to ten days, the joint pain can be debilitating and, in some cases, prolonged.
For UK-based diaspora families travelling “back home” during holidays, weddings, funerals or cultural festivals, mosquito-borne diseases are a real risk, particularly in subtropical and tropical climates.
This is why the introduction of the IXCHIQ vaccine in 2025 was initially welcomed as a protective option for travellers. However, safety monitoring has now led to permanent usage restrictions.
New Guidance for Travellers Planning Trips
Under the updated advice, healthcare professionals must carry out a detailed benefit-risk assessment before offering the vaccine to eligible individuals.
As a precaution, the vaccine should be administered at least 30 days before travel. The reasoning is practical and important. If a serious adverse reaction were to occur, the individual would still be in the UK, with access to familiar healthcare systems and without potential language barriers abroad.
For many diaspora families, travel plans are often arranged quickly, sometimes in response to emergencies. This 30-day recommendation means that early planning is now more important than ever.
What This Means for Older Diaspora Travellers
One of the most significant implications of this announcement is for older members of the diaspora community. The vaccine is now explicitly not recommended for those aged 60 and above.
Many older parents and grandparents travel regularly between the UK and countries in Africa or the Caribbean. Those with common chronic conditions such as high blood pressure or diabetes are also excluded under the new guidance, regardless of age.
This does not mean they cannot travel, but it does mean that alternative protective measures, such as mosquito bite prevention, become even more critical.
Understanding Risk Without Panic
The MHRA has emphasised that its role is to ensure that medicines and vaccines are both effective and acceptably safe. The restriction does not mean the vaccine is unsafe for everyone. Rather, it reflects updated evidence and a precautionary approach for certain higher-risk groups.
The Commission on Human Medicines concluded that for healthy adults between 18 and 59 years old without the specified medical conditions, the benefits of vaccination still outweigh the risks when exposure is likely.
The key message is informed decision-making.
If you are planning to travel to a region where chikungunya is present, it is important to consult your GP, pharmacist or travel clinic well in advance. Discuss your medical history honestly, including any chronic conditions, and ask about both vaccine eligibility and additional protective strategies.
Reporting Side Effects and Staying Informed
Anyone who suspects they are experiencing a side effect after receiving the vaccine is encouraged to speak to a healthcare professional and report it through the MHRA’s Yellow Card scheme. This system allows patients and clinicians to report suspected adverse reactions, helping regulators monitor safety in real time.
For diaspora communities, especially those who may receive medical advice across different countries, clear communication with UK-based healthcare providers is essential.
A Broader Conversation About Global Health and Mobility
This development also highlights a broader reality of diaspora life. Movement between the UK and countries in Africa, Asia and the Caribbean is common and often necessary. But global mobility brings global health considerations.
As more vaccines are developed for tropical diseases, ongoing safety monitoring will continue to shape who can safely receive them.
For now, the message from UK regulators is measured but firm. IXCHIQ remains available for certain adults, but not for older individuals or those with specific underlying health conditions.
At Chijos News Diaspora Health Desk, our priority is ensuring that UK-based communities have accurate, accessible information that supports safe travel and informed choices.
If you are planning to travel this year, especially to regions where chikungunya is present, speak to a healthcare professional early. Protecting your health should be part of your travel checklist, alongside tickets and visas.
As always, preparation is power.
